Rate of heart failure and 1-year survival for older people receiving low-dose β-blocker therapy after myocardial infarction

Lancet

Volumn 356, Issue 9230, 2000, Pages 639-644

  Rochon, Paula A ^a   Tub, Jack V ^a   Anderson, Geoffrey M ^a   Gurwitz, Jerry H ^b   Clark, Jocalyn P ^c   Lau, Paula ^a   Szalai, John Paul ^a   Sykora, Kathy ^a   Naylor, C David ^a  

^a INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ACETYLSALICYLIC ACID; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LABETALOL; METOPROLOL; NADOLOL; PINDOLOL; PROPRANOLOL; SOTALOL; TIMOLOL;

AGED; ARTICLE; COHORT ANALYSIS; COMORBIDITY; DRUG CONTRAINDICATION; FEMALE; HEART FAILURE; HEART INFARCTION; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONBIOLOGICAL MODEL; PRIORITY JOURNAL; SURVIVAL RATE;

EID: 0343090401     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02606-4     Document Type: Article

References (33)

1. Gottlieb S.S., McCarter R.J., Vogel R.A. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 339:1998;489-497.
2. Lechat P., Packer M., Chalon S., Cucherat M., Arab T., Boissel J.P. Clinical effects of beta-adrenergic blockade in chronic heart failure. a meta-analysis of double-blind, placebo-controlled, randomized trials Circulation. 98:1998;1184-1191.
3. Krumholz H.M., Radford M.J., Wang Y., Chen J., Heiat A., Marciniak T.A. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction. National Cooperative Cardiovascular Project JAMA. 280:1998;623-629.
4. Rochon P.A., Anderson G.M., Tu J.V.et al. Use of beta-blocker therapy in the elderly following acute myocardial infarction. Can Med Assoc J. 161:1999;1403-1408.
5. Rochon P.A., Anderson G.M., Tu J.V.et al. Age and gender-related use of low dose drug therapy. the need to manufacture low-dose therapy and evaluate the minimum effective dose J Am Geriatr Soc. 47:1999;954-959.
6. Wilcox R.G., Roland J.M., Banks D.C., Hampton J.R., Mitchell J.R.A. Randomised trial comparing propranolol with atenolol in immediate treatment of suspected myocardial infarction. BMJ. 280:1980;885-888.
7. Hjalmarson A., Herlitz J., Holmberg S., Ryden L., Swedberg K. The Goteborg metoprolol trial: effects on mortality and morbidity in acute myocardial infarction. Circulation. 67(suppl I):1983;I-26-I-32.
8. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 304:1981;801-807.
9. A randomized trial of propranolol in patients with acute myocardial infarction. JAMA. 247:1982;1707-1714.
10. Boissel J.P., Leizorovicz A., Pilolet H., Peyrieux J.C. Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. Am J Cardiol. 66:1990;251-260.
11. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (merit-hf). Lancet. 353:1999;2001-2007.
12. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 353:1999;9-13.
13. Hjalmarson A., Goldstein S., Fagerberg B.et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HR). JAMA. 283:2000;1295-1302.
14. Tu J., Naylor C.D., Austin P. Temporal changes in the outcomes of acute myocardial infarction in Ontario 1992-1996. Can Med Assoc J. 161:1999;1257-1261.
15. Tu J.V., Austin P., Naylor C.D., Iron K., Zhang H. Acute myocardial infarction outcomes in Ontario: methods appendix. Naylor C.D., Slaughter P.M. Cardiovascular health and services in Ontario: an ICES Atlas. 1999;25-30 Institute for Clinical Evaluative Sciences, Toronto.
16. Cox J.L., Melady M.P., Chen E., Naylor C.D. Towards improved coding of acute myocardial infarction in hospital discharge abstracts. a pilot project Can J Cardiol. 13:1997;351-358.
17. International classification of diseases, ninth revision, clinical modification. 1992;the Commission, Ann Arbor.
18. McClellan M., McNeil B.J., Newhouse J.P. Does more intensive treatment of acute myocardial infarction in the elderly reduce mortality? Analysis using instrumental variables. JAMA. 272:1994;859-866.
19. Pashos C.L., Newhouse J.P., McNeil B.J. Temporal changes in the care and outcomes of elderly patients with acute myocardial infarction, 1987 through 1990. JAMA. 270:1993;1832-1836.
20. Physicians' desk reference. 51st edn. 1997;Medical Economics Company Inc, Montvale.
21. British national formulary. 1997;British Medical Association and Pharmaceutical Press, London.
22. Compendium of pharmaceuticals and specialities, 33rd edn. 1998;Canadian Pharmacists Association, Ottawa.
23. Fallen E.L., Cairns J., Dafoe W.et al. Management of the postmyocardial infarction patient: a consensus report - revision of 1991 CCS guidelines. Can J Cardiol. 11:1995;477-486.
24. Rochon P.A., Fortin P.R., Dear K.B.G., Minaker K.L.T.C. Reporting of age data in clinical trials of arthritis: deficiencies and solutions. Arch Intern Med. 153:1993;243-248.
25. Charlson M.E., Pompei P.A., Ales K.L. MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 40:1987;373-383.
26. Deyo R.A., Cherkin D.C., Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 45:1992;613-619.
27. Agresti A. Categorical data analysis. 1990;John Wiley and Sons, New York.
28. Wen S.W., Hernandez R., Naylor C.D. Pitfalls in nonrandomized outcome studies. the case of incidental appendectomy with open cholecystectomy JAMA. 274:1995;1687-1691.
29. Schocken D.D. Arrieta MI, Leaverton PE, Ross EA. Prevalence and morbidity rate of congestive heart failure in the United States. J Am Coll Cardiol. 20:1992;301-306.
30. Barron H.V., Viskin S., Lundstrom R.J.et al. Beta blocker dosages and mortality after myocardial infarction. data from a large health maintenance organization Arch Intern Med. 158:1998;449-453.
31. Sharpe N. Benefit of beta-blockers for heart failure: proven in 1999. Lancet. 353:1999;1988-1999.
32. Gurwitz J.H., Col N.F., Avorn J. The exclusion of the elderly and women from clinical trials in acute myocardial infarction. JAMA. 268:1992;1417-1422.
33. Rochon P.A., Clark J.P., Binns M.A., Patel V., Gurwitz J.H. Reporting of gender-related information in clinical trials of drug therapy for myocardial infarction. Can Med Assoc J. 159:1998;321-327.